Sagimet Biosciences (SGMT) Equity Average (2022 - 2026)

Sagimet Biosciences' Equity Average history runs 5 years deep, the most recent figure standing at $106.9 million for Q1 2026.

• In Q1 2026, Equity Average fell 27.46% year-over-year to $106.9 million; the TTM figure through Mar 2026 stood at $106.9 million (down 27.46% YoY), while the FY2025 annual figure was $133.6 million, up 8.23% from the prior year.
• Equity Average was $106.9 million for Q1 2026 at Sagimet Biosciences, down from $115.3 million in the prior quarter.
• In the past five years, Equity Average ranged from a high of $186.7 million in Q2 2024 to a low of -$195.6 million in Q2 2023.
• Historically, Equity Average has averaged $39.6 million across 5 years, with a median of $115.3 million in 2025.
• The sharpest annual moves came in 2024 and 2025: Equity Average soared 452.08% in 2024, then fell 29.54% in 2025.
• A 5-year view of Equity Average shows it stood at -$183.8 million in 2022, then jumped by 151.41% to $94.5 million in 2023, then soared by 72.8% to $163.2 million in 2024, then declined by 29.36% to $115.3 million in 2025, then dropped by 7.28% to $106.9 million in 2026.
• The last three Equity Average figures came in at $106.9 million (Q1 2026), $115.3 million (Q4 2025), and $124.7 million (Q3 2025), per Business Quant data.